Protara Completes Enrollment in Phase 2b Trial for IV Choline Chloride
Event summary
- Protara Therapeutics completed enrollment of 24 patients in the Phase 2b open-label dose confirmation phase of the THRIVE-3 trial for IV Choline Chloride.
- Interim results from this cohort are expected in 4Q 2026.
- The trial targets patients with intestinal failure dependent on parenteral support and choline deficiency.
- IV Choline Chloride has Orphan Drug and Fast Track designations from the FDA.
- The Phase 3 trial will involve approximately 100 patients in a randomized, double-blind, placebo-controlled study.
The big picture
Protara's progress in the THRIVE-3 trial positions IV Choline Chloride as a potential first-of-its-kind treatment for choline deficiency in parenteral support patients. The trial's completion of enrollment marks a critical step toward addressing a significant unmet need in liver function management for patients with intestinal failure. The strategic significance lies in the potential to tap into a niche but critical market segment, leveraging regulatory advantages to expedite market entry.
What we're watching
- Regulatory Pathway
- Whether the Fast Track and Orphan Drug designations will accelerate FDA approval for IV Choline Chloride.
- Clinical Efficacy
- The pace at which interim results from the Phase 2b cohort will demonstrate safety and efficacy in elevating plasma choline levels.
- Market Potential
- How the approval and commercialization of IV Choline Chloride will impact the approximately 30,000 long-term parenteral support patients in the U.S.
Related topics
